User profiles for Jakub Hlávka
 | Jakub HlávkaMasaryk University, Brno, Czech Republic; USC Schaeffer Center, USC Keck School of … Verified email at usc.edu Cited by 1157 |
[BOOK][B] Assessing the preparedness of the US health care system infrastructure for an Alzheimer's treatment
Assessing the Preparedness of the US Health Care System Infrastructure for an Alzheimer's
Treatment -- Appendix Page 1 CORPORATION Appendix for RR-2272-BIOG Assessing the …
Treatment -- Appendix Page 1 CORPORATION Appendix for RR-2272-BIOG Assessing the …
Macroeconomic consequences of the COVID-19 pandemic
We estimate the economic impacts of COVID-19 in the US using a disaster economic
consequence analysis framework implemented by a dynamic computable general equilibrium (…
consequence analysis framework implemented by a dynamic computable general equilibrium (…
[HTML][HTML] Biosimilar cost savings in the United States: initial experience and future potential
AW Mulcahy, JP Hlavka, SR Case - Rand health quarterly, 2018 - ncbi.nlm.nih.gov
The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the 2010
Patient Protection and Affordable Care Act (ACA), authorized the US Food and Drug …
Patient Protection and Affordable Care Act (ACA), authorized the US Food and Drug …
Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: projecting the impact on the cost and wait times
… Soeren Mattke, Tobias Bittner, and Jakub Hlávka worked on conception and design of the
study, whereas Sang Kyu Cho, Tobias Bittner, and Mark Hanson worked on the acquisition …
study, whereas Sang Kyu Cho, Tobias Bittner, and Mark Hanson worked on the acquisition …
[PDF][PDF] Toward a sustainable blood supply in the United States
…, R Chaturvedi, SR Case, J Hlávka… - … , Santa Monica, CA, 2016 - rand.org
A robust, sustainable blood system is a crucial component of every health care system. The
availability of safe blood and blood products is a prerequisite for various health care services…
availability of safe blood and blood products is a prerequisite for various health care services…
[HTML][HTML] Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment
No disease-modifying therapy is currently available for Alzheimer's disease, but therapies
are in development, and one may become available in the near future. Based on results from …
are in development, and one may become available in the near future. Based on results from …
[BOOK][B] Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer's treatment
■ If a therapy becomes available in 2021, we estimate that average annual wait times for
diagnosis and treatment in Canada could peak at 28 months and persist for decades if there …
diagnosis and treatment in Canada could peak at 28 months and persist for decades if there …
Remote opportunities for scholars in Ukraine
In 2001, Science published the Report “Binding of DCC by netrin-1 to mediate axon guidance
independent of adenosine A2B receptor activation” by E. Stein et al.(1). In 2015, the …
independent of adenosine A2B receptor activation” by E. Stein et al.(1). In 2015, the …
The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey
Despite recent setbacks, disease-modifying treatments (DMTs) for Alzheimer disease (AD)
might become available within a few years. These DMTs are likely to be used in the early …
might become available within a few years. These DMTs are likely to be used in the early …
[HTML][HTML] Factors associated with biosimilar exclusions and step therapy restrictions among US commercial health plans
… Jakub P. Hlávka. The funder played no role in the design, collection, analysis, and interpretation
of the data or the decision to publish the … Hlávka have no conflicts of interest to report. …
of the data or the decision to publish the … Hlávka have no conflicts of interest to report. …